Anteris Technologies Global Corp.
Moat Score — Anteris Technologies Global Corp.
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Anteris holds 47 active and 75 pending patents covering its single-piece biomimetic valve design, ADAPT anti-calcification tissue process, and ComASUR delivery system, plus registered trademarks (DurAVR, ADAPT, ComASUR). The ADAPT platform has a long clinical track record (55,000+ patients) in other applications, but DurAVR itself has no approved product or brand recognition in TAVR yet, so the IP is real but largely unmonetized. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | Anteris is pre-commercial with minimal revenue (~$1.9M in FY2025) and relies on external contract manufacturers and suppliers (Aran Biomedical, Harvey Industries, NPX Medical, Switchback Medical) rather than owning scaled, low-cost production. It has no demonstrated cost advantage versus Edwards or Medtronic, which benefit from decades of manufacturing scale. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | DurAVR has no commercial sales and therefore no demonstrated pricing power. If approved, its differentiated biomimetic design could support premium pricing versus three-piece valves, but this is entirely speculative pending clinical data and reimbursement negotiations against entrenched incumbents. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | As a physical implantable medical device, DurAVR exhibits no network effect — value to one patient or physician does not increase as more patients or physicians adopt the device, beyond the generic benefit of accumulating clinical registry data. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Once physicians are trained and hospitals credentialed on a specific TAVR platform, switching costs are typically high — but today that inertia favors Edwards and Medtronic, not Anteris, which must overcome existing physician familiarity and hospital purchasing relationships as a new entrant. Modest future switching-cost moat exists only if Anteris successfully converts implanting centers to its platform. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | Anteris operates at a tiny fraction of the scale of Edwards and Medtronic, which dominate global TAVR volumes; the company is burning ~$50M+ per half-year on clinical trials and manufacturing scale-up with almost no offsetting revenue, the opposite of an efficient-scale moat. |